Datavault AI (NASDAQ: DVLT) announced a binding term sheet with Wellgistics Health (NASDAQ: WGRX) to create DelivMeds AI, a healthcare platform combining AI-driven pharmacy optimization, blockchain-enabled smart contracts, biometric verification and direct-to-consumer healthcare delivery through three concurrent transactions, including an expanded PharmacyChain(TM) license, acquisition of QOLPOM intellectual property and a controlling stake in Tollo Health. The combined transactions carry an expected approximate asset value of $4 billion, subject to an independent fairness opinion, and are intended to support a national rollout of data-driven healthcare delivery and patient engagement solutions.
Datavault AI Inc. (“Datavault AI” or the “Company”) (NASDAQ:DVLT), a provider of data monetization, credentialing, digital engagement, and real-world asset (‘RWA’) tokenization technologies, today entered into a fully binding term sheet (the “Binding Term Sheet”) with Wellgistics Health, Inc. (“Wellgistics”) (NASDAQ:WGRX), a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence (AI) platform EinsteinRx™ into its patented blockchain-enabled smart contracts platform PharmacyChain™, to build Wellgistics into DelivMeds AI, a healthcare company that will focus on improving data driven outcomes following the completion of three concurrent transactions: 1) the expansion of Datavault AI’s previously disclosed PharmacyChain™ license (“License”) to include Healthcare-as-a-Service (“HaaS”)-related intellectual property; 2) the acquisition of the QOLPOM intellectual property from EOS Technology Holdings, Inc. (EOS Holdings) and Scilex Holding Company (“Scilex”) (NASDAQ:SCLX) that enables wearables-driven biometric confirmation of pharmacodynamic drug effect and biometric confirmation named-patient to receive home drug delivery; and 3) the acquisition of a controlling stake in Tollo Health, LLC which manufactures unique medical foods and dietary supplements for GLP-1 muscle loss, acute viral infections and chronic viral infection syndromes, proprietary consumer engagement technology, and proprietary marketing channels. Gerald Commissiong has concurrently been appointed Interim Co-CEO of Wellgistics. Together, the three transactions forming DelivMeds carry an expected approximate combined asset value of $4 billion, subject to an independent fairness opinion.
Wellgistics Pharmacy monthly revenue increased from approximately $0.1 million in November 2025 to approximately $0.6 million in April 2026, based on preliminary unaudited results
TAMPA, FL / ACCESS Newswire / May 15, 2026 / Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics" or the "Company"), a leading healthcare technology and pharmaceutical distribution company, today announced that it will report financial results for the first quarter of 2026 on Tuesday, May 19, 2026.
Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Wellgistics Health Inc. (NASDAQ: WGRX) resulting from allegations that Wellgistics may have issued materially misleading business information to the investing public.
Get a pulse on the US markets on Tuesday by checking out the most active stocks in today's session. Discover the stocks that are leading the way in terms of trading volume and market activity.
Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Wellgistics Health Inc. (NASDAQ: WGRX) resulting from allegations that Wellgistics may have issued materially misleading business information to the investing public.
Let's delve into the US markets on Friday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.
